For the quarter ending 2025-09-30, CRVS has $80,474K in assets. $8,706K in debts. $2,867K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 2,867 | 14,691 | ||
| Marketable securities | 62,822 | 59,716 | ||
| Accounts receivable - related party | 32 | 86 | ||
| Prepaid and other current assets | 1,223 | 1,287 | ||
| Total current assets | 66,944 | 75,780 | ||
| Property and equipment, net | 221 | 249 | ||
| Operating lease right-of-use asset | 927 | 1,012 | ||
| Investment in angel pharmaceuticals | 11,530 | 11,794 | ||
| Other assets | 852 | 626 | ||
| Total assets | 80,474 | 89,461 | ||
| Accounts payable | 1,974 | 3,137 | ||
| Operating lease liability | 379 | 355 | ||
| Accrued and other liabilities | 5,721 | 5,013 | ||
| Total current liabilities | 8,074 | 8,505 | ||
| Operating lease liability | 632 | 728 | ||
| Total liabilities | 8,706 | 9,233 | ||
| Common stock 0.0001 par value 290,000,000 shares authorized at september 30, 2025 and december 31, 2024 74,681,872 and 67,899,779 shares issued and outstanding at september 30, 2025 and december 31, 2024 | 7 | 7 | ||
| Additional paid-in capital | 472,793 | 471,184 | ||
| Accumulated other comprehensive loss | -1,060 | -1,148 | ||
| Accumulated deficit | -399,972 | -389,815 | ||
| Total stockholders' equity | 71,768 | 80,228 | ||
| Total liabilities and stockholders' equity | 80,474 | 89,461 | ||
Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (CRVS)